Thank you, Mr. Chairman. There are differences between the two lists. The one that we look after is much more current and much more active. One of the problems with NIHB is they are very slow to change, add or delete drugs or bring in new drugs. They are not very forward about giving us information about when changes have been made. They have also capped that program, so they are looking at controlling costs at every opportunity. So there is a difference. The one that we administer through extended health benefits is much more actively managed. Thank you.